SCHEMBL18548577

SCHEMBL18548577

CN(C)C1CCCN(I)C1

nearest known ligand 0.39

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20843917 1.00 PIM1 (0.39) PIM1
SCHEMBL20843909 1.00 PIM1 (0.39) PIM1
SCHEMBL18123348 0.86
SCHEMBL14260295 0.86
SCHEMBL690715 0.77 PIM1 (0.36) PIM1
SCHEMBL15616406 0.75
SCHEMBL24721280 0.74 SIGMAR1 (0.42) PIM1
SCHEMBL13935740 0.74 SIGMAR1 (0.42) PIM1
SCHEMBL690716 0.74 SIGMAR1 (0.42) PIM1
SCHEMBL9883843 0.74 PIM1 (0.34) PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3339294-B1 QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER THEREOF AS AXL INHIBIOTOR SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) 2021-04-14 EP disclosed
EP-3225619-B1 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2020-10-14 EP disclosed
WO-2020028706-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2020-02-06 WO disclosed
EP-3225619-A1 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) 2017-10-04 EP disclosed
WO-2017028797-A1 PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER 暨南大学 2017-02-23 WO disclosed